Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy

Autor: Alexander Bachmann, Aurélie Bisiaux, Roland Brosch, Molly A. Ingersoll, Frédéric D. Birkhäuser, Gilles Marchal, Micheline Lagranderie, Mickael Orgeur, Joel R. Gsponer, Christian Wetterauer, Cyrill A. Rentsch, Matthew L. Albert, Christiane Bouchier, Claire Biot, George N. Thalmann

Publikováno v: European Urology
European Urology, Elsevier, 2014, 66 (4), pp.677-688. ⟨10.1016/j.eururo.2014.02.061⟩
European Urology, 2014, 66 (4), pp.677-688. ⟨10.1016/j.eururo.2014.02.061⟩
Eur Urol

BACKGROUND: Whether the commonly used bacillus Calmette-Guerin (BCG) strains Connaught and Tice confer different treatment responses in non-muscle-invasive bladder cancer (NMIBC) is unknown. OBJECTIVES: To compare clinical efficacy, immunogenicity, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ff25b2981c709a330c86d4b82b4317a
https://pubmed.ncbi.nlm.nih.gov/25760254